
Namakkal eggs break out of shell, go to US
It continues to be the country's leading hub for egg exports, totalling 15 crore eggs every month. Some of the top export destinations include the UAE, Bahrain, Maldives, Oman and some African countries.
Jahan R, secretary of Egg and Poultry Products Exporters Association, said eggs from Namakkal are exported in refrigerated containers, each carrying 4,72,320 eggs valued at around $35,000 per container or approximately `30 lakh based on the current exchange rate.
'While Andhra Pradesh leads India in egg production, Namakkal ranks first in exports due to its proximity to ports, resulting in shorter transit times. For instance, shipping eggs from Andhra Pradesh to Middle Eastern countries can take up to 14 days, whereas from Namakkal, it takes just 4 days,' he said.
Vangili Subramaniam, president of the Tamil Nadu Egg Poultry Farmers Marketing Society, said, 'Only a tenth of Namakkal's 1,300 farms export eggs, but the region's export market has expanded due to disruptions caused by the Ukraine war and bird flu outbreaks in major egg-producing countries like Turkey and US. Namakkal has not been affected by bird flu, largely due to its decentralised poultry farm model which helps contain the spread of diseases effectively.'
Further, he added that before 2014, a transport assistance subsidy of about 7% of the Free on Board (FOB) value was provided by the central government, making Namakkal's eggs more competitive internationally through reduced export costs. However, since then, this subsidy has dropped to nearly one per cent. 'If the government brings back these subsidies, Namakkal exporters can compete better with countries like Turkey.'
Subramaniam said, 'The egg export business will grow steadily only if our government secures permanent trade agreements with countries that aren't self-sufficient in production.'
'The opening of the US market is a significant development for us,' said C Sasikumar, a local poultry owner. In terms of infrastructure, most exporting farms in Namakkal operate both production facilities and dedicated setups for cleaning, processing, grading and packing eggs.
However, countries like UAE require eggs from biosecurity-certified farms with a compartment licence, and building such infrastructure requires major investment. Further, obtaining this state and central-approved certification is also a lengthy process, discouraging new exporters and local players. Additionally, stricter standards in markets like Qatar — which now demand only 'AA' or 'A' grade eggs weighing at least 60 grams — pose difficulties, as Namakkal eggs typically weigh around 55 grams, he added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Business Standard
2 hours ago
- Business Standard
Reliance Industries faces scrutiny as EU targets diesel from Russian crude
By Yongchang Chin, PR Sanjai and Rakesh Sharma The oil-procurement patterns of India's Reliance Industries Ltd. are coming under scrutiny after the European Union announced new restrictions on diesel made from Russian crude. Reliance bought Abu Dhabi's Murban crude in a rare purchase late last week, traders said, adding that it picked up the cargo soon after Friday's sanction package. The private refiner isn't a regular buyer of the UAE grade, a premium crude that tends to be costlier than its regular appetite of Russian Urals and heavier Middle Eastern varieties. Separately, people familiar with Reliance's import plans said the company has begun seeking to diversify its crude purchases away from Russia, its single-biggest source of oil so far this year. The people asked not to be identified as they aren't authorised to speak publicly. Reliance, a mega refiner owned by billionaire Mukesh Ambani, and other Indian processors have been among the world's top beneficiaries of Moscow's war in Ukraine. Europe shunned Russian crudes soon after the 2022 invasion, leading to deep cargo discounts that enticed Indian refiners to crank up opportunistic buying for production of fuels such as diesel, which it resold to western customers. An Airbus jet owned by Reliance Industries landed in Moscow's Vnukovo airport on Wednesday morning, according to data from flight tracking website FlightRadar24. The plane last took a flight to Russia last December, the data shows. It's not clear if Ambani was on board. A Reliance spokesman wasn't immediately available to comment. According to ship-tracking data compiled by Kpler, Russia has supplied almost half of Reliance's crude imports so far this year. In turn, around one-fifth of the processor's total product exports were sold to Europe. The process of refining Russian crude into diesel for sales into Europe has put Reliance in the line of fire of EU's latest pressure on Moscow, with the ban set to take effect Jan. 21 next year. While it's too early to tell if Reliance will pivot dramatically away from Russia, traders say there are some initial signs of the company seeking alternatives from places such as the Middle East. Still, it's unclear how the mega refiner will source close to 600,000 barrels a day of crude from other producers, and at what cost, they added. So far, the South Asian nation has been critical of latest EU sanctions, with India's Foreign Secretary Vikram Misri on Tuesday saying that there was a need for 'balance' when secondary sanctions are imposed on the purchase of Russian oil and gas.


Time of India
3 hours ago
- Time of India
Natco Pharma to buy over 35% in South Africa's Adcock Ingram
Natco Pharma, based in Hyderabad, is set to acquire a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for ₹2,000 crore. This all-cash deal provides Natco Pharma with a strong entry into high-growth African markets and expands its product offerings. The acquisition, expected to finalize in four months, aligns with Natco's strategy to grow in emerging markets. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Hyderabad-based Natco Pharma on Wednesday said it has agreed to buy a 35.75% stake in Adcock Ingram , South Africa's second-largest drugmaker, for '2,000 all-cash deal will give Natco Pharma a foothold in some high-growth African markets besides an opportunity to expand its product Nannapaneni, chief executive officer and vice chairman of Natco Pharma, told ET that the Adcock deal is aligned with the company's plan of expanding its presence in emerging markets . "Besides, this was within our valuation range," he said the company reserves the right of first refusal in case the shareholders of Adcock Ingram plan to divest additional equity stake. The Bidwest group holds 64.25% stake in the company."Adcock Ingram will be delisted from the JSE (Johannesburg Stock Exchange) if the transaction proceeds," Natco Pharma said in a statement, adding that the estimated transaction completion time is four months, assuming that there are no regulatory told investors over a call that the deal is a significant step as it would have taken Natco Pharma decades to build business in Africa on its Ingram has a presence across segments-prescription, OTC ( over-the-counter drugs ), consumer products and the hospitals the first half of FY25, Adcock Ingram recorded sales of $262 million. In FY24, its sales stood at $536 million and EBITDA at $78 million. It had a gross margin of 33.4% in EV/EBITDA for the Natco deal is 7.83, according to an investor presentation by Natco Pharma said it can potentially bring significant value through its research and development programmes, dossier approvals, intellectual property sharing, experience in regulated market operations, sourcing and global marketing for the new markets in Africa and regulated markets in the the investor call, Nannapaneni hinted at another deal under examination but refused to share any details. For FY25, Natco Pharma recorded sales of '4,784 crore and a profit after tax of '1,883 crore. The company had a cash reserve of '3,000 crore, of which '2,000 crore will be used for the Adcock deal.


Economic Times
3 hours ago
- Economic Times
Natco Pharma to buy over 35% in South Africa's Adcock Ingram
Synopsis Natco Pharma, based in Hyderabad, is set to acquire a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for ₹2,000 crore. This all-cash deal provides Natco Pharma with a strong entry into high-growth African markets and expands its product offerings. The acquisition, expected to finalize in four months, aligns with Natco's strategy to grow in emerging markets. Representative image. Mumbai: Hyderabad-based Natco Pharma on Wednesday said it has agreed to buy a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for '2,000 crore. The all-cash deal will give Natco Pharma a foothold in some high-growth African markets besides an opportunity to expand its product portfolio. Rajeev Nannapaneni, chief executive officer and vice chairman of Natco Pharma, told ET that the Adcock deal is aligned with the company's plan of expanding its presence in emerging markets. "Besides, this was within our valuation range," he said the company reserves the right of first refusal in case the shareholders of Adcock Ingram plan to divest additional equity stake. The Bidwest group holds 64.25% stake in the company. "Adcock Ingram will be delisted from the JSE (Johannesburg Stock Exchange) if the transaction proceeds," Natco Pharma said in a statement, adding that the estimated transaction completion time is four months, assuming that there are no regulatory delays. Nannapaneni told investors over a call that the deal is a significant step as it would have taken Natco Pharma decades to build business in Africa on its own. Adcock Ingram has a presence across segments-prescription, OTC (over-the-counter drugs), consumer products and the hospitals business. For the first half of FY25, Adcock Ingram recorded sales of $262 million. In FY24, its sales stood at $536 million and EBITDA at $78 million. It had a gross margin of 33.4% in EV/EBITDA for the Natco deal is 7.83, according to an investor presentation by Natco Pharma said it can potentially bring significant value through its research and development programmes, dossier approvals, intellectual property sharing, experience in regulated market operations, sourcing and global marketing for the new markets in Africa and regulated markets in the the investor call, Nannapaneni hinted at another deal under examination but refused to share any details. For FY25, Natco Pharma recorded sales of '4,784 crore and a profit after tax of '1,883 crore. The company had a cash reserve of '3,000 crore, of which '2,000 crore will be used for the Adcock deal.